Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A film having a metallic luster is easier to manufacture and exhibits little degradation over time, an article having the film formed thereon, and a manufacturing method for the film having a metallic luster. The film, which has a metallic luster, according to one aspect of the present invention, is characterized by containing a thiophene polymer. The manufacturing method for the film which has a metallic luster, according to another aspect of the present invention, is characterized by a thiophene being polymerized using an oxidizing agent and made into a solution containing the thiophene polymer, and then coating and drying the solution containing the thiophene polymer on an article. The article having the film which has a metallic luster formed thereon, according to another aspect of the present invention, is characterized by containing a thiophene polymer.

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.

Abstract: Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker.

Abstract: Provided is a liquid crystal compound that can obtain a high-speed response and a sufficient contrast ratio in switching of a display device. A compound represented by formula (1) described below is utilized. In formula (1), ring A is naphthylene, phenantolylene or anthracenylene, and in the groups, at least one piece of hydrogen may be replaced by halogen, —CH3, —C2H5, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2 or —OCH2F; and X1, X2, X3, X4, X5, Y1, Y2, Y3, Y4 and Y5 are independently hydrogen or fluorine, but at least two or more of X1, X2, X3, X4, X5, Y1, Y2, Y3, Y4 and Y5 is fluorine.

Abstract: Disclosed is a high quality display device which avoids complicated element structure, and does not unnecessarily reduce portability. The display device comprises: a pair of substrates which are disposed facing each other, and on each of which electrodes are formed; and a material layer which is sandwiched between the pair of substrates. The material layer contains: a coloring material which changes color upon the application of a voltage; and a light-emitting material which emits light upon photoexcitation.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A tunable external resonator laser is mode-hop-free for broadband and has a laser chip which emits light; a lens which collimates the light emitted from the laser chip, a diffraction grating which diffracts the light collimated by the lens, a support body to which the diffraction grating is fixed, and a movable mirror which reflects the light diffracted by the diffraction grating, wherein the diffraction grating is arranged a prescribed distance apart from a Littman-type tunable external resonator laser arrangement in which the movable mirror rotates on a pivot which is the intersection point of the surface of said movable mirror and the surface of the diffraction grating.

Abstract: The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other.

Abstract: A medicament is useful for prevention or treatment of muscle injury. A novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, a preventing or therapeutic agent for muscle injury containing the extract as an active ingredient. The preventing or therapeutic agent for muscle injury contains the extract as an active ingredient is extremely useful as a highly effective and highly safe medicament.

Abstract: The present invention is intended to provide an artificial polyclonal immunoglobulin composition or artificial immunoglobulin fragment composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other. An artificial immunoglobulin fragment composition is also provided that can include at least one polypeptide comprising an amino acid sequence set forth in SEQ ID NOS: 1 to 204, for example, SEQ ID NO. 31.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: An electrodeposition element is provided which includes a first substrate including a first member and an electrode arranged above the first member, a second substrate arranged opposite to the first substrate and including an electrode, and an electrolyte layer arranged between the electrodes of the first substrate and the second substrate, and including an electrodeposition material that contains silver. When a voltage is applied between the electrodes of the first substrate and the second substrate such that the first substrate side is negative and the second substrate side is positive, a reflective surface made of a silver thin film and reflecting light, which is incident from a direction normal to the first and second substrates, in a direction not parallel to the incident direction of the light is formed above the electrode of the first substrate.

Abstract: A method for producing a crystalline amino acid involves a step of irradiating a saturated solution of an amino acid with an optical vortex and depositing a crystalline amino acid in the saturated solution of amino acid. It is desirable that the amino acid is at least one of alanine, arginine, asparagine, asparagine acid, cysteine, glutamine, glutamine acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and derivatives thereof.

Abstract: A pharmaceutical composition includes a physiological solution containing a dendritic cell as an active component and plasma. The dendritic cell expresses a CD1d molecule on a surface thereof, and the CD1d molecule is bound with ?-galactosylceramide. A concentration of the plasma is 40 volume/volume % or higher to a total volume of the composition.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is the possibility for new application of optical vortices. In order to do so, the method for producing an organic helical structure according to the present invention entails irradiating the surface of macromolecules that exhibit a photoisomerization reaction with an optical vortex, thereby forming a nanoscale helical structure on the surface of the macromolecules. In this case, it is preferable that the macromolecules exhibiting a photoisomerization reaction are azo polymer and/or spiropyran-polymer macromolecules. Moreover, it is preferable that the step for forming a nanoscale helical structure is repeated, and that a plurality of nanoscale helical structures are formed in two dimensions on the surface of the macromolecules. It is also preferable that the optical vortex is circularly polarized light, and that the total angular momentum (J) of the optical vortex is not 0.

Abstract: Tumor growth was found to be significantly suppressed in vivo by inhibiting both miRNA containing 5?-AACACUG-3? as a seed sequence and miRNA containing 5?-AAUACUG-3? as a seed sequence. The inhibition significantly altered the proportion of subpopulations of tumor cells and reduced the tumorigenicity in all subpopulations. The inhibition also exerted a remarkable tumor-shrinking effect on already-formed tumors. The present invention provides novel therapeutic potential against tumor.